The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Abstract
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval under Phase I–III trials. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival. Recently, an antioxidant drug, edaravone, developed by Mitsubishi Tanabe Pharma was found to be effective in halting ALS progression during early stages. The newly approved drug edaravone is a force multiplier for ALS treatment. This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures. Moreover, we also discussed the pressing issues and challenges of ALS clinical trials and drug developments as well as future outlook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Edaravone can prevent the development of the disease.451”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [451]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,058
Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30115-1 · Cited by 935
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
Astrocyte dysfunction in neurological disorders: a molecular perspective
Seifert, G., Schilling, K., & Steinhäuser, C. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1870 · Cited by 799
When Experiments Travel: Clinical Trials and the Global Search for Human Subjects
Petryna, A. (2009) · DigitalGeorgetown (Georgetown University Library) · doi:10.1515/9781400830824 · Cited by 755
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Jiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536
Westeneng, H.-J., Debray, T. P. A., Visser, A. E., van Eijk, R. P. A., Rooney, J. P. K., Calvo, A., Martin, S., McDermott, C. J., Thompson, A. G., Pinto, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30089-9 · Cited by 524
Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014
Mehta, P., Kaye, W., Raymond, J., Wu, R., Larson, T., Punjani, R., Heller, D., Cohen, J., Peters, T., Muravov, O., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6707a3 · Cited by 458
Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., Hamada, C., Kondo, K., Yoneoka, T., Akimoto, M., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.959024 · Cited by 365
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub2 · Cited by 313
Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration
Kaplan, A., Spiller, K. J., Towne, C., Kanning, K. C., Choe, G. T., Geber, A., Akay, T., Aebischer, P., & Henderson, C. E. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.009 · Cited by 306
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
Lazic, S. E., & Essioux, L. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-37 · Cited by 237
Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS
Heiman-Patterson, T. D., Deitch, J. S., Blankenhorn, E. P., Erwin, K. L., Perreault, M. J., Alexander, B. K., Byers, N., Toman, I., & Alexander, G. M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.02.006 · Cited by 236
Lazic, S. E., & Essioux, L. (2016) · Cited by 182
Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one
Yamamoto, Y., Kuwahara, T., Watanabe, K., & Watanabe, K. (1996) · Redox Report · doi:10.1080/13510002.1996.11747069 · Cited by 160
OH Radical Scavenging Activity of Edaravone: Mechanism and Kinetics
Pérez‐González, A., & Galano, A. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp110400t · Cited by 145
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis
Sawada, H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1319937 · Cited by 139
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
Meininger, V., Bensimon, G., Bradley, W. G., Brooks, B. R., Douillet, P., Eisen, A., Lacomblez, L., Leigh, P. N., & Robberecht, W. (2004) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820410019602 · Cited by 130
Generation of a Motor Nerve Organoid with Human Stem Cell-Derived Neurons
Kawada, J., Kaneda, S., Kirihara, T., Maroof, A. M., Levi, T., Eggan, K. C., Fujii, T., & Ikeuchi, Y. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.09.021 · Cited by 125
Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease
Jaiswal, M. K., Zech, W., Goos, M., Leutbecher, C., Ferri, A., Zippelius, A., Carrì, M. T., Nau, R., & Keller, B. U. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-64 · Cited by 122
Self-citationALS clinical trials: Do enrolled patients accurately represent the ALS population?
Chiò, A., Canosa, A., Gallo, S., Cammarosano, S., Moglia, C., Fuda, G., Calvo, A., Gabriele, M., & For the PARALS group (2011) · Neurology · doi:10.1212/wnl.0b013e318232ab9b · Cited by 117
Hatzipetros, T., Bogdanik, L. P., Tassinari, V. R., Kidd, J. D., Moreno, A. J., Davis, C., Osborne, M. A., Austin, A., Vieira, F. G., Lutz, C. M., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.10.013 · Cited by 113
Prevalence of Amyotrophic Lateral Sclerosis — United States, 2012–2013
Mehta, P., Kaye, W., Bryan, L. N., Larson, T. C., III, Copeland, T. P., Wu, J., Muravov, O. I., & Horton, D. K. (2016) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6508a1 · Cited by 105
Jaiswal, M. K., & Keller, B. U. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050831 · Cited by 98
Self-citationSpiller, K. J., Cheung, C., Restrepo, C. R., Kwong, L. K., Stieber, A., Trojanowski, J. Q., & Lee, V. M. Y. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1457-16.2016 · Cited by 87
The need for littermate controls
Holmdahl, R., & MALISSEN, B. (2011) · European Journal of Immunology · doi:10.1002/eji.201142048 · Cited by 80
The Blackwell Companion to Hinduism
(2005) · Blackwell Publishing Ltd eBooks · doi:10.1111/b.9780631215356.2005.x · Cited by 77
PGC-1 is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis
Eschbach, J., Schwalenstocker, B., Soyal, S. M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.-C., Birve, A., Meyer, T., Dupuis, L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt202 · Cited by 75
Miller, R. G., Moore, D. H., Forshew, D. A., Katz, J. S., Barohn, R. J., Valan, M., Bromberg, M. B., Goslin, K. L., Graves, M. C., McCluskey, L. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7a5 · Cited by 70
Targets in ALS: designing multidrug therapies
Carrì, M. T., Grignaschi, G., & Bendotti, C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.03.009 · Cited by 63
Jami, M., Salehi-Najafabadi, Z., Ahmadinejad, F., Hoedt, E., Chaleshtori, M. H., Ghatrehsamani, M., Neubert, T. A., Larsen, J. P., & Møller, S. G. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.024 · Cited by 62
Knight, A. (2007) · ALTEX · doi:10.14573/altex.2007.4.320 · Cited by 60
Calcium, mitochondria, and the pathogenesis of ALS: the good, the bad, and the ugly
Jaiswal, M. K. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00199 · Cited by 57
Self-citationHow can we improve clinical trials in amyotrophic lateral sclerosis?
Gordon, P. H., & Meininger, V. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.147 · Cited by 57
Jaiswal, M. K. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-26 · Cited by 56
Self-citationGarbuzova-Davis, S. N., Kurien, C., Thomson, A., Falco, D., Ahmad, S., Staffetti, J. F., Steiner, G. A., Abraham, S., James, G. V., Mahendrasah, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00993-0 · Cited by 49
Scrutinizing enrollment in ALS clinical trials: Room for improvement?
Bedlack, R., Pastula, D. M., Welsh, E., Pulley, D., & Cudkowicz, M. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802195913 · Cited by 43
THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1362000 · Cited by 43
Jaiswal, M. K. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00295 · Cited by 41
Self-citationTakahashi, F., Takei, K., Tsuda, K., & Palumbo, J. (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1361442 · Cited by 39
Jaiswal, M. K. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.206635 · Cited by 29
Self-citationGender-based effect of statins on functional decline in amyotrophic lateral sclerosis
Nefussy, B., Hirsch, J., Cudkowicz, M., & Drory, V. E. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.10.011 · Cited by 25
Paine, A., & Jaiswal, M. K. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00219 · Cited by 15
Self-citation
Cited by
Bonafede, R., Turano, E., Scambi, I., Busato, A., Bontempi, P., Virla, F., Schiaffino, L., Marzola, P., Bonetti, B., & Mariotti, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103651 · Cited by 146
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients
Zeng, Q., Shen, J., Chen, K., Zhou, J., Liao, Q., Lu, K., Yuan, J., & Bi, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-69845-8 · Cited by 127
Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
Cho, H., & Shukla, S. (2020) · Pharmaceuticals · doi:10.3390/ph14010029 · Cited by 124
Risk factors and emerging therapies in amyotrophic lateral sclerosis
Nowicka, N., Juranek, J., Juranek, J. K., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112616 · Cited by 106
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Metadata
- Authors
- Jaiswal, M. K.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2018-08-12
- Volume
- 39
- Issue
- 2
- Pages
- 733-748
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2885679472
- Cited by
- 451
- References
- 55
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.